WuXi AppTec has completed the sale of its subsidiaries WuXi Clinical and WuXi MedKey to Hillhouse. WXAT Shanghai, a unit of WuXi AppTec, has received the first instalment payment of RMB1.54 billion from Hillhouse, and all conditions for the transaction have been fulfilled. As a result, WuXi Clinical and WuXi MedKey are no longer included in WuXi AppTec's consolidated financial statements. The share transfer registration procedures are expected to be finalized by December 31, 2025. The transaction is preliminarily estimated to generate a net profit after tax of approximately RMB0.96 billion for WuXi AppTec, according to the company.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. WuXi AppTec Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251215-11956223), on December 15, 2025, and is solely responsible for the information contained therein.
Comments